Each year the pharmaceutical industry develops new drugs that go a long way towards fighting some of the world’s worst diseases. For instance, Bristol-Meyers Squibb recently received FDA (Food & Drug Administration) approval for Opdivo, a drug that significantly boosts the survival rate for sufferers of advanced melanoma. However, one major obstacle stands in the way of Opdivo’s ability to help patients: price. One year of treatment with the drug costs $150,000 per patient, an impossibly tall order for many Continue reading
